📊 SRTAW Key Takeaways
Is Strata Critical Medical, Inc. (SRTAW) a Good Investment?
Strong 34.3% revenue growth masks deeply unprofitable operations (-11.3% operating margin) and critical negative free cash flow burn of $58.5M. The positive net income appears driven by non-operating items rather than sustainable operations, requiring urgent operational improvements.
Why Buy Strata Critical Medical, Inc. Stock? SRTAW Key Strengths
- Strong top-line growth of 34.3% YoY
- Fortress balance sheet with zero debt and $279.1M equity
- Excellent liquidity position with 6.38x current ratio
SRTAW Stock Risks: Strata Critical Medical, Inc. Investment Risks
- Deeply negative operating margin (-11.3%) with core business unprofitable
- Critical cash burn: -$58.5M free cash flow against only $31M cash on hand creates ~6-month runway
- Earnings quality concern: positive net income (+21.0% margin) conflicts with negative operating income and operating cash flow, indicating non-operating gains masking operational losses
- Negative operating cash flow of -48.9M is unsustainable and threatens long-term viability
Key Metrics to Watch
- Operating cash flow trajectory and path to positive FCF
- Operating margin expansion toward breakeven
- Cash burn rate sustainability and potential capital raise requirements
Strata Critical Medical, Inc. (SRTAW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.38x current ratio provides a solid financial cushion.
SRTAW Profit Margin, ROE & Profitability Analysis
SRTAW vs Services Sector: How Strata Critical Medical, Inc. Compares
How Strata Critical Medical, Inc. compares to Services sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Strata Critical Medical, Inc. Stock Overvalued? SRTAW Valuation Analysis 2026
Based on fundamental analysis, Strata Critical Medical, Inc. appears fundamentally strong relative to the Services sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Strata Critical Medical, Inc. Balance Sheet: SRTAW Debt, Cash & Liquidity
SRTAW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Strata Critical Medical, Inc.'s revenue has grown significantly by 290% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.35 indicates the company is currently unprofitable.
SRTAW Revenue Growth, EPS Growth & YoY Performance
SRTAW Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $36.1M | -$2.0M | $-0.03 |
| Q2 2025 | $67.9M | -$3.7M | $-0.05 |
| Q1 2025 | $51.5M | -$3.5M | $-0.04 |
| Q3 2024 | $71.4M | $289.0K | $0.00 |
| Q2 2024 | $61.0M | -$11.3M | $-0.15 |
| Q1 2024 | $45.3M | -$4.2M | $-0.06 |
| Q3 2023 | $45.7M | $289.0K | $0.00 |
| Q2 2023 | $35.6M | -$2.6M | $-0.04 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Strata Critical Medical, Inc. Dividends, Buybacks & Capital Allocation
SRTAW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Strata Critical Medical, Inc. (CIK: 0001779128)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 14, 2026 | DEF 14A | ny20060135x1_def14a.htm | View → |
| Mar 18, 2026 | 4 | xslF345X06/wk-form4_1773864134.xml | View → |
| Mar 10, 2026 | 4 | xslF345X05/wk-form4_1773178208.xml | View → |
| Mar 10, 2026 | 4 | xslF345X05/wk-form4_1773178187.xml | View → |
| Mar 10, 2026 | 4 | xslF345X05/wk-form4_1773178155.xml | View → |
❓ Frequently Asked Questions about SRTAW
What is the AI rating for SRTAW?
Strata Critical Medical, Inc. (SRTAW) has an AI rating of HOLD with 55% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SRTAW's key strengths?
Claude: Strong top-line growth of 34.3% YoY. Fortress balance sheet with zero debt and $279.1M equity.
What are the risks of investing in SRTAW?
Claude: Deeply negative operating margin (-11.3%) with core business unprofitable. Critical cash burn: -$58.5M free cash flow against only $31M cash on hand creates ~6-month runway.
What is SRTAW's revenue and growth?
Strata Critical Medical, Inc. reported revenue of $197.1M.
Does SRTAW pay dividends?
Strata Critical Medical, Inc. does not currently pay dividends.
Where can I find SRTAW SEC filings?
Official SEC filings for Strata Critical Medical, Inc. (CIK: 0001779128) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SRTAW's EPS?
Strata Critical Medical, Inc. has a diluted EPS of $0.50.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SRTAW a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Strata Critical Medical, Inc. has a HOLD rating with 55% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SRTAW stock overvalued or undervalued?
Valuation metrics for SRTAW: ROE of 14.8% (sector avg: 16%), net margin of 21.0% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
Should I buy SRTAW stock in 2026?
Our dual AI analysis gives Strata Critical Medical, Inc. a combined HOLD rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is SRTAW's free cash flow?
Strata Critical Medical, Inc.'s operating cash flow is $-48.9M, with capital expenditures of $9.6M. FCF margin is -29.7%.
How does SRTAW compare to other Services stocks?
Vs Services sector averages: Net margin 21.0% (avg: 10%), ROE 14.8% (avg: 16%), current ratio 6.38 (avg: 1.5).